BiotechTube
Home/Pipeline/Aspen Neuroscience Collaboration

Aspen Neuroscience Collaboration

Parkinson's Disease

Phase 1/2Active

Key Facts

Indication
Parkinson's Disease
Phase
Phase 1/2
Status
Active
Company
Mytos

About Mytos

Mytos is an automated CDMO for regenerative medicine, leveraging its iDEM™ automation platform to reduce the cost and labor of cell therapy manufacturing. The company targets the critical bottleneck of scalable production for clinical-stage biotechs, offering a 'one-stop-shop' from process development to regulatory support. Backed by over $24M in funding and strategic partnerships with organizations like the CGT Catapult, Mytos aims to make curative cell therapies commercially viable and widely accessible.

View full company profile

Therapeutic Areas

Parkinson's DiseaseSensorineural Hearing LossCorneal BlindnessBone Fractures

Other Parkinson's Disease Drugs

DrugCompanyPhase
NPT200-11Neuropore TherapiesPhase 1
VXX-301VaxxinityPreclinical
BAN2802BioArcticPhase 1
CNM-Au8ClenePhase 2
hpSC-Derived Neural/Dopaminergic CellsInternational Stem CellPreclinical/Early Clinical
SLS-004Seelos TherapeuticsPreclinical
SLS-007Seelos TherapeuticsPreclinical
Parkinson's Disease ResearchProgenaBiomeResearch
A9 Dopaminergic Neuron TherapyTrailhead BiosystemsPre-clinical
golexanoloneUmecrine CognitionPreclinical
Parkin Activator ProgramProgenraPre-clinical
Not SpecifiedAsceneuronNot Disclosed